Gain insight into the mind of a scientist-turned-investor. Eventide Managing Director and Senior Research Analyst Kyle Rasbach, MD, PhD, shares his unique perspective on the healthcare industry and why he made the career shift from developing therapies to investing in them.
Author

Kyle Rasbach, PhD, PharmD

Managing Director, Senior Research Analyst

Kyle Rasbach, PhD, PharmD, serves as a Managing Director for Eventide’s private investing line of business, and a Senior Research Analyst for other Eventide investments. 

Dr. Rasbach has extensive experience in clinical pharmacology, basic science, and healthcare equity research. Prior to joining Eventide, Dr. Rasbach was a Managing Partner at Pappas Capital, a life science venture capital firm that invests across biotechnology, biopharmaceuticals, drug delivery, and medical devices. Earlier in his career he was an equity research analyst and Vice President at T. Rowe Price, where he managed pharmaceutical, specialty pharmaceutical and biotechnology investments. Prior to joining T. Rowe, Dr. Rasbach was an equity research associate and Vice President at Cowen and Company, where he covered global pharmaceutical equities.

Dr. Rasbach holds a PhD in Pharmaceutical and Biomedical Sciences as well as a PharmD from the Medical University of South Carolina; he completed his postdoctoral training in the laboratory of Bruce Spiegelman at the Harvard Medical School. He also holds an MBA from The Citadel and a BS in Biology from Denison University.